British Journal of Clinical Pharmacology · 1979 · 15 citations · 7 references
MedicinePharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyPreventive CardiologyBlood Pressure ControlBlood Pressure ManagementHypertension ControlHypertension ManagementHypertension PharmacotherapyHypertensive DisordersAntihypertensive Drug TherapyAntihypertensive PharmacologyCross-over EffectsHeart RateMedication Adverse EffectsSubjective Drug Effects
1 Twenty patients with essential hypertension completed a double-blind, dose-tritrated, cross-over comparison of methyldopa and labetalol. 2 Average lying BPs (systolic/diastolic) were reduced by 28/15 mmHg with methyldopa and by 23/15 mmHg with labetalol. 3 Average standing BPs (systolic/diastolic) were reduced by 29/14 mmHg with methyldopa and by 29/15 mmHg with labetalol. 4 Both lying and standing heart rates were reduced with labetalol. 5 It is concluded that the antihypertensive properties of labetalol and methyldopa are similar but that larger patient populations are needed to study the relative incidence of subjective adverse effects.
7
Controlled comparison of labetalol and propranolol in the management of severe hypertension.
D. J. Pugsley, Bruce K. Armstrong, Maria Nassim et al. · PubMed · 1976 · 47 citations
Medicine, Cardiology, Pharmacology +12
Double-blind trial of labetalol.
John M. Kane, Ian Gregg, DA Richards · PubMed · 1976 · 47 citations